September 16, 2021 9:38 AM
SINGAPORE (THE BUSINESS TIMES) – Allay Therapeutics, a clinical-stage biotech start-up that makes pain-relief products, raised US$60 million (S$80.45 million) in a Series C fund-raising round led by US-based healthcare-focused venture capital firm Arboretum Ventures.
